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Abstract
It is estimated that viral infections contribute to 15–20% of all human cancers. As obligatory intracellular parasites, viruses encode proteins
that reprogram host cellular signaling pathways that control proliferation, differentiation, cell death, genomic integrity, and recognition by the
immune system. These cellular processes are governed by complex and redundant regulatory networks and are surveyed by sentinel mechanisms
that ensure that aberrant cells are removed from the proliferative pool. Given that the genome size of a virus is highly restricted to ensure
packaging within an infectious structure, viruses must target cellular regulatory nodes with limited redundancy and need to inactivate surveillance
mechanisms that would normally recognize and extinguish such abnormal cells. In many cases, key proteins in these same regulatory networks are
subject to mutation in non-virally associated diseases and cancers. Oncogenic viruses have thus served as important experimental models to
identify and molecularly investigate such cellular networks. These include the discovery of oncogenes and tumor suppressors, identification of
regulatory networks that are critical for maintenance of genomic integrity, and processes that govern immune surveillance.
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With 10.9 million new cases and 6.7 million deaths per year,
cancer is a devastating disease, presenting an immense disease
burden to affected individuals and their families as well as
health care systems [1]. Development of treatment and preven-
tion strategies to manage this disease critically depends on our
understanding of cancer cells and the mechanism(s) through
which they arise. In general terms, carcinogenesis represents a
complex, multi-step process. During the past 30 years it has
become exceedingly apparent that several viruses play signif-
icant roles in the multistage development of human neoplasms;
in fact, approximately 15% to 20% of cancers are associated
with viral infections [2,3]. Oncogenic viruses can contribute to
different steps of the carcinogenic process, and the association
of a virus with a given cancer can be anywhere from 15% to
100% [3]. In addition to elucidating the etiology of several⁎ Corresponding authors. Tel.: +1 617 525 4282; fax: +1 617 525 4283.
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doi:10.1016/j.bbadis.2007.12.005human cancers, the study of oncogenic viruses has been invalu-
able to the discovery and analysis of key cellular pathways that
are commonly rendered dysfunctional during carcinogenesis in
general.
2. Historic context
The belief in the infectious nature of cancer originated in
classical times as evidenced by accounts of “cancer houses” in
which many dwellers developed a certain cancer. Observations
that married couples sometimes could be affected by similar
cancer types and that cancer appeared to be transmitted from
mother to child lent further support to an infectious etiology of
tumors. However, during the 19th century, extensive investiga-
tions failed to demonstrate a carcinogenic role for bacteria,
fungi, or parasites leading to the belief that cancer is not caused
by an infectious agent. Despite the prevailing dogma, a small
number of researchers hypothesized that the failure to detect an
infectious cause of cancer did not necessarily mean that the
general idea of the infectious nature of cancer was invalid.
Rather, they hypothesized that the causal organism had merely
Table 1
Evans and Mueller guidelines [21]
Epidemiologic guidelines
1. Geographic distribution of viral infection corresponds with that of the tumor,
adjusting for the presence of known co-factors
2. Viral markers are higher in case subjects than in matched control subjects
3. Viral markers precede tumor development, with a higher incidence of tumors
in persons with markers than those without
4. Tumor incidence is decreased by viral infection prevention
Virologic guidelines
1. Virus can transform cells in vitro
2. Viral genome is present in tumor cells, but not in normal cells
3. Virus induces the tumor in an experimental animal
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standard microscopy may indeed be the culprits. Despite in-
creasing evidence to suggest that infectious entities of sub-
microscopic size may be associated with cancer, acceptance of
this hypothesis took many years. M'Fadyan and Hobday de-
scribed the cell-free transmission of oral dog warts with cell-free
extracts in 1898 [4], and Ciuffo published similar transmission
studies with human warts in 1907 [5]. The significance of these
findings was not fully appreciated since warts are benign
hyperplasias and not malignant tumors. In 1908, Ellermann and
Bang demonstrated that leukemia in birds could be transmitted
from animal to animal via extracts of leukemic cells or serum
from diseased birds [6]. However, at the time it was not realized
that this was the first successful transmission of a naturally
occurring tumor, as leukemia was not yet accepted as a cancer. In
1911, Peyton Rous produced solid tumors in chickens using cell-
free extracts from a transplantable sarcoma [7]. This study was
also met with considerable skepticism due to the fact that infec-
tious cancers of birds were not considered valid models for
human cancers. In fact, the importance of this study was not fully
appreciated until the finding that murine leukemias could be
induced by viruses [8,9]. Over the next two decades numerous
additional animal oncogenic viruses were isolated, Rous was
awarded the Noble Prize for his pioneering work in 1966, and the
importance of the early work on animal tumor viruses was
finally recognized. In fact, the enthusiasm for these findings
contributed in no small part to President Nixon signing the
National Cancer Act into law in 1971 and declaring the “War on
Cancer”.
After the successes of the animal tumor virus field, scientists
began the search for human tumor viruses. However, initial
attempts to isolate transmissible carcinogenic viruses from human
tumors proved disappointing, once again raising doubts about the
existence of human cancer viruses. The discovery of Epstein–
Barr virus (EBV) by electron microscopy (EM) in cells cultured
from Burkitt's lymphoma (BL) in 1964 [10] and the discovery of
hepatitis B virus (HBV) in human sera positive for hepatitis B
surface antigen in 1970 [11], together with the development of
animal and cell culture model systems, resulted in a renewed
interest in the roles of viruses in human cancer. The search for
additional human tumor viruses continued, and, despite several
setbacks, the ultimate acknowledgment of the causal relationship
between viruses and human cancer occurred during the early
1980s, due in large part to three major discoveries during that
time. In 1983 and 1984, human papillomavirus (HPV) 16 and 18
were isolated from human cervical cancer specimens [12,13].
Additionally, although the link betweenHBVand liver cancer had
been suspected for decades, the results of a large-scale epide-
miological study provided a compelling link between persistent
HBV infection and liver carcinogenesis [14]. The third major
discovery was the isolation of the human T-cell leukemia virus
(HTLV-I) fromT-cell lymphoma/leukemia patients [15,16]. Since
their initial discovery, associations of these viruses with cancers at
other anatomical sites have been discovered.Moreover, new links
between viruses, most notably hepatitis C virus (HCV) [17] and
human herpes virus 8 (HHV8)/Kaposi's sarcoma herpesvirus
(KSHV) [18], and human cancers have been discovered. Today,viruses are accepted as bona fide causes of human cancers, and it
has been estimated that between 15 and 20% of all human cancers
may have a viral etiology [2,3].
3. General aspects of viral carcinogenesis
The infectious nature of oncogenic viruses sets them apart
from other carcinogenic agents. As such, a thorough study of
both the pathogenesis of viral infection and the host response is
crucial to a full understanding of the resulting cancers. Such an
understanding, in turn, has increased our knowledge of cellular
pathways involved in growth and differentiation and neoplasia
as a whole.
Even though human oncogenic viruses belong to different
virus families and utilize diverse strategies to contribute to
cancer development, they share many common features. One
key feature is their ability to infect, but not kill, their host cell. In
contrast to many other viruses that cause disease, oncogenic
viruses have the tendency to establish long-term persistent in-
fections. Consequently, they have evolved strategies for evading
the host immune response, which would otherwise clear the
virus during these persistent infections. Despite the viral eti-
ology of several cancers, it appears that the viruses often may
contribute to, but are not sufficient for, carcinogenesis; in fact,
the majority of tumor virus-infected individuals do not develop
cancer, and in those patients that do develop cancer many years
may pass between initial infection and tumor appearance.
Additional co-factors, such as host immunity and chronic
inflammation, as well as additional host cellular mutations, must
therefore also play an important role in the transformation
process. Additionally, there is an obvious geographical distribu-
tion of many virus-associated cancers, which is possibly due to
either geographical restriction of the virus or access to essential
co-factors. Thus, the long-term interactions between virus and
host are key features of the oncogenic viruses, as they set the
stage for a variety of molecular events that may contribute to
eventual virus-mediated tumorigenesis [19].
4. Criteria for defining an etiologic role for viruses in
cancer
In many cases, viral carcinogenesis is associated with an
abortive, non-productive infection. Hence, the original Koch
Table 2
Hill criteria for causality [22,23]
1. Strength of association (how often is the virus associated with the tumor?)
2. Consistency (has the association been observed repeatedly?)
3. Specificity of association (is the virus uniquely associated with the tumor?)
4. Temporal relationship (does virus infection precede tumorigenesis?)
5. Biologic gradient (is there a dose response with viral load?)
6. Biologic plausibility (is it biologically plausible that the virus could
cause the tumor?)
7. Coherence (does the association make sense with what is known about
the tumor?)
8. Experimental evidence (is there supporting laboratory data?)
Table 4
Properties of viruses implicated in human cancers
Virus Viral Taxonomy Genome Human Cancers
BKV Polyomaviridae dsDNA ∼5.2 kb Prostate?
JCV Polyomaviridae dsDNA ∼5.2 kb Brain?
SV40 Polyomaviridae dsDNA ∼5.2 kb Brain, bone, mesothelioma?
HERVs Retroviridae dsRNA/DNA? Seminomas, breast,
ovarian, melanoma?
HMTV Retroviridae dsRNA/DNA? Breast?
TTV Circoviridae ssDNA 3.8 kb Gastrointestinal, lung, breast,
and myleoma?
BKV, BK virus; HERVs, human endogenous retroviruses; HMTV, human
mammary tumor virus; JCV, JC virus; SV40, simian virus 40; and TTV, Torque
teno virus.
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applied, as oftentimes no disease causing infectious entity can be
isolated from a tumor. Therefore, it is often difficult to establish a
viral cause for a human cancer. As a result, different guidelines
have been proposed to aid in establishing a causal relationship
between viruses and human cancers (Tables 1 and 2) [21–23].
Although some of the guidelines are difficult to meet and others
are not applicable to all viruses, the guidelines are nonetheless
quite useful when evaluating a putative association between a
virus and a human malignancy.
5. Human oncogenic viruses
Human tumor viruses belong to a number of virus families,
including the RNA virus families Retroviridae and Flaviviridae
and the DNAvirus families Hepadnaviridae, Herpesviridae, and
Papillomaviridae. To date, viruses that are compellingly asso-
ciated with human malignancies include; (i) HTLV-1 (adult T-cell
leukemia (ATL)) [15], (reviewed in [24]); (ii) HPV (cervical
cancer, skin cancer in patients with epidermodysplasia verruci-
formis (EV), head and neck cancers, and other anogenital cancers)
[12,13], (reviewed in [25–28]); iii) HHV-8 (Kaposi's sarcoma
(KS), primary effusion lymphoma, and Castleman's disease) [18],
(reviewed in [29,30]) (iv) EBV (Burkitt's Lymphoma (BL),
nasopharyngeal carcinoma (NPC), post-transplant lymphomas,
and Hodgkin's disease) [10], (reviewed in [31–33]); and (v) HBV
andHCV (hepatocellular carcinoma (HCC)) [11,17], (reviewed in
[34–38]). Viruses with potential roles in human malignancies
include; (i) simian vacuolating virus 40 (SV40) (brain cancer,
bone cancer, and mesothelioma) [39]; (ii) BK virus (BKV)
(prostate cancer) [40], (reviewed in [41]); (iii) JC virus (JCV)
(brain cancer) [42], (reviewed in [41]); (iv) human endogenous
retroviruses (HERVs) (germ cell tumors, breast cancer, ovarianTable 3
Properties of human tumor viruses
Virus Viral taxonomy Genome Cell tropism
EBV Herpesviridae dsDNA 172 kb ∼90 ORFs Oropharyng
HBV Hepadnaviridae dsDNA 3.2 kb 4 ORFs Hepatocyte
HCV Flaviviridae dsRNA 9.4 kb 9 ORFs Hepatocyte
HPV Papillomaviridae dsDNA 8 kb 8–10 ORFs Squamous
HTLV-1 Retroviridae dsRNA 9.0 kb 6 ORFs T-cells
KSHV Herpesviridae dsDNA 165 kb ∼90ORFs B cells
ATL, adult T-cell leukemia; BL, Burkitt's lymphoma; EBV, Epstein–Barr virus; HBV
human papillomavirus; HTLV-1, human T-cell leukemia virus; KSHV, Kaposi's sarccancer, and melanoma) [43,44]; (v) human mammary tumor virus
(HMTV) (breast cancer) (reviewed in [45]; and (vi) Torque teno
virus (TTV) (gastrointestinal cancer, lung cancer, breast cancer,
and myeloma) [46]. General information about viruses with
known and potential associations with human cancer is provided
in Tables 3 and 4, respectively. Studies of the RNA and DNA
tumor viruses have led to the discovery of oncogenes and tumor
suppressors and have greatly added to our understanding of the
etiology of carcinogenesis, both virally and non-virally induced.
5.1. RNA tumor viruses
Although retroviruses have been associated with many
animal tumors, to date, only one human retrovirus, HTLV-1, has
been associated with human cancers. The biology of HTLV-1
will be discussed in more detail in the next section. Studies with
animal retroviruses have been instrumental in establishing the
concept of oncogenic viruses and led to the discovery of onco-
genes and tumor suppressors as well as other key regulators of
cellular signal transduction pathways. Hence, animal retro-
viruses warrant some discussion in this review.
The advent of modern tumor virology came about with the
development of an in vitro transformation assay for Rous
sarcoma virus (RSV) [47]. This assay allowed for the genetic
analysis of the retroviral life cycle and retrovirus-induced
transformation in cell culture (reviewed in [48–52]). Retro-
viruses are classified as either simple or complex viruses based
on the organization of their genomes. Shortly after infection, the
viral RNA genome is reverse-transcribed by the virally encoded
reverse transcriptase into a double-stranded DNA copy, which
then integrates into the host chromosome and is expressed underHuman cancers
eal epithelial cells, B-cells BL, NPC, lymphomas
s, white blood cells HCC
s HCC
epithelial cells Cervical, oral, and anogenital cancer
ATL
Kaposi sarcoma, primary effusion lymphoma
, hepatitis B virus; HCC, hepatocellular carcinoma; HCV, hepatitis C virus; HPV,
oma-associated herpesvirus; and NPC, nasopharyngeal carcinoma.
Fig. 1. Schematic depiction of the major biological activities that contribute to
the transforming activities of HTLV-1. See text for details.
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integrated, proviruses are rarely lost from the host chromosome.
As a consequence of integration, and of particular relevance
when considering oncogenesis, is the ability of simple retro-
viruses to acquire and transduce cellular genetic material or to
activate or inactivate cellular genes via provirus insertion. It was
the analysis of this group, the transducing retroviruses, that led
to the finding that the RSV transforming gene, v-src, hybridized
to cellular sequences; ultimately this finding led to the discovery
of proto-oncogenes, a group of cellular genes that mediate viral
carcinogenesis and have critical roles in the control of cell
growth and differentiation (reviewed in [48–52]). Since this
initial discovery, numerous animal retroviruses with oncogenic
properties have been discovered, and, as is the case with src, the
transduced retroviral oncogenes are derived from cellular
sequences and are not necessary for viral replication [50,52].
The erroneous recombination events that allow for acquisition
of host cell derived coding sequences often leave viral genomes
mutated and the virus defective for replication. As such, these
viruses are dependent on replication competent helper viruses to
provide the necessary replication functions in trans. Normal
cellular transcriptional and translational controls are lost once an
acquired cellular sequence is incorporated into the viral genome,
and the over-expression of a proto-oncogene under the control of
strong viral promoters can cause malignant transformation.
Moreover, since the acquired proto-oncogene is not necessary
for viral replication but is replicated through the same error prone
mechanisms as the viral genome, retrovirally acquired proto-
oncogenes are subject to frequent mutation and some “activating”
proto-oncogene mutations endow the infected cell with a growth
advantage and hence are selected for over time. Such oncogene
transducing retroviruses efficiently transform cells in culture and
cause tumors in experimental animals with very short latency
periods. However, this mechanism is relatively rarely seen in
animals in the wild and has not been documented in humans.
Nonetheless, this ‘oncogene piracy’ has proven to be quite useful
in laboratory studies of the actions of oncogenes in cancer. Most
remarkably, mutations in cellular oncogenes that arise in human
tumors as a consequence of mutagenic insults are often similar or
identical to those discovered in transducing carcinogenic retro-
viruses [53].
A second group, the cis-acting retroviruses, does not contain
host cell derived sequences but transforms cells by integrating in
the vicinity of a cellular proto-oncogene or tumor suppressor.
Unlike the transducing retroviruses, the cis-acting retroviruses
retain all of their viral genes and thus can replicate without the
aid of a helper virus. cis-acting retroviruses cause malignancy in
only a percentage of infected animals after a longer latency
period than that required for transducing retroviruses, and they
generally do not efficiently transform cells in culture. Insertional
mutagenesis is a common mechanism observed for rodent,
feline, and avian retroviruses, such as avian leukosis virus and
mouse mammary tumor virus (MMTV). Whereas there is no
compelling evidence that such a mechanism significantly con-
tributes to human carcinogenesis, cloning of affected genes led
to the discovery of numerous oncogenes, such as int-1 [54,55],
int-2 [55], Pim-1 [56], bmi-1 [57], Tpl-1 [58], and Tpl-2 [59],that importantly contribute to the development of human neo-
plasms. Moreover, the finding that the Friend murine leukemia
virus had integrated into both alleles of the p53 gene in an
erythroleukemic cell line provided critical evidence that p53 was
a tumor suppressor rather than an oncogene as was originally
suspected [60].
5.1.1. Human T-cell leukemia virus (HTLV-1)
Of more significance to human carcinogenesis, the third
mechanism of retroviral oncogenesis does not involve transmis-
sion of a mutated version of a cellular proto-oncogene or dys-
regulated expression of proto-oncogenes or tumor suppressor
genes near or at the integration site. The latency period between
the initial infection and development of a neoplasm with this
group of viruses is often in the range of several years to several
decades. The best-studied example of these viruses is HTLV-1,
the first human retrovirus to be discovered that is clearly
associated with a human malignancy [15,16]. HTLV-1 is a delta-
type complex retrovirus and is the etiologic agent of ATL and
tropical spastic paraparesis/HTLV-1-associated myelopathy
(TSP/HAM). HTLV-1 is endemic to Japan, South America,
Africa, and the Caribbean [61,62]. While it is estimated that
approximately 20 million people worldwide are infected with
HTLV-1 [63], only a small percentage (2–6%) will develop
ATL [64]. The long clinical latency, together with the relatively
low cumulative lifetime risk of a carrier developing ATL, indi-
cates that HTLV-1 infection is not sufficient to elicit T-cell
transformation. While the exact cellular events remain unclear, a
variety of steps, including virus, host cell, and immune factors,
are implicated in the leukemogenesis of ATL [65] (Fig. 1).
A number of studies indicate that the multifunctional viral
accessory protein Tax is the major transforming protein of HTLV-
1 [66–73]. Tax modulates expression of viral genes though the
viral long terminal repeats (LTRs), and also dysregulates multiple
cellular transcriptional signaling pathways including nuclear
factor kappa B (NF-κB) [74–85], serum responsive factor (SRF)
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[91–94], and activator protein 1 (AP-1) [95,96]. Rather than
binding to promoter or enhancer sequences directly, Tax interacts
with cellular transcriptional co-activators such as p300/CBP
[94,97–104], and P/CAF [105]. In addition to its role in transcrip-
tional regulation, Tax is also able to functionally inactivate p53
[106,107], p16INK4A [108,109], and the mitotic checkpoint pro-
tein, mitotic arrest deficient (MAD) 1 [110–112]. Additionally,
the C-terminal PDZ domain-bindingmotif of Tax, which interacts
with the tumor suppressor hDLG [113], is important for
transformation of rat fibroblasts [114] and inducing interleukin-
2-independent growth of mouse T-cells [115].
Unlike other well-established DNA tumor viruses, which
generally require continuous expression of viral oncoproteins to
sustain transformation (reviewed in [116]), tax transcripts are
detected in only 40% of ATLs [117], suggesting that Tax may be
needed to initiate transformation, but may not be necessary for
maintenance of the transformed phenotype. Tax is the main
target of the host's cytotoxic T lymphocyte (CTL) response;
therefore, the repression of Tax expression allows infected host
cells to evade immunesurveillance and allows for the prefer-
ential selection of these cells during the progression of ATL
[117]. There are several mechanisms by which ATL cells lose
Tax expression, including the loss of the viral promoter for tax
transcription, the 5′-LTR [117], mutation of the tax gene [118],
and epigenetic changes in the 5′-LTR [119,120].
Tax has also been implicated in inducing genomic instability,
most prominently aneuploidy, which, as is the case in many
cancers, is a hallmark of ATL [112]. Recent studies have shown
that HTLV-1 Tax expression causes multipolar mitoses, from
which aneuploidy can arise, in two ways [121–123]. First, Tax
targets the cellular TAX1BP2 protein, which normally blocks
centriole replication, thus causing numerical centrosome aber-
rations [121]. Second, it has been proposed that Tax engages
RANBP1 during mitosis and fragments spindle poles, thereby
provoking multipolar, asymmetrical chromosome segregation.
Together, these mechanisms help explain the long-standing
observations of aneuploidy and multipolar spindles in ATL cells
(“flower cells”) [124]. In addition, several ATL cell lines have
been demonstrated to lack an intact mitotic spindle assembly
checkpoint [112], which may be related to binding to MAD1
[110,111]. Evidence that Tax may act as a mitotic mutator gene,
greatly increasing the incidence of mitotic abnormalities, is
consistent with reports that Tax binds to and activates the
anaphase-promoting complex/cyclosome (APC/C), thereby
promoting premature securin degradation and mitotic exit,
thus contributing to aneuploidy [125–127]. However, this con-
cept is not fully accepted as a recent study found that Tax did not
increase securin degradation [128].
As mentioned previously, alterations of the 5′-LTR, such as
deletions or hypermethylation, are common in ATL cells. As a
result, the transcription of viral genes encoded on the plus strand is
often repressed. On the other hand, the 3′-LTR is conserved and
hypomethylated in all ATLs [120]. The HBZ mRNA is tran-
scribed from the 3′-LTR [129,130] and is expressed in all ATL
cells [131]. Suppression of HBZ gene transcription inhibits the
proliferation of ATL cells; additionally HBZ gene expressionpromotes the proliferation of a human T-cell line [131]. It appears
that HBZ may have a bimodal function at the mRNA and protein
levels, as the RNA form of HBZ supports T-cell proliferation
through regulation of the E2F1 pathway, whereas HBZ protein
suppresses Tax-mediated viral transcription through the 5′-LTR
[129].
5.1.2. Hepatitis C virus (HCV)
HCV is the etiologic agent of posttransfusion and sporadic
non-A, non-B hepatitis [17] and infects approximately 2% of the
population worldwide, although the prevalence of HCV in-
fection varies by geographical location [132]. Persistent in-
fection with HCV is associated with hepatitis, hepatic steatosis,
cirrhosis, and hepatocellular carcinoma (HCC) [133–137]. HCV
is a single-stranded RNA virus of the Hepacivirus genus in the
Flaviviridae family and is the only positive-stranded RNA
virus among the human oncogenic viruses. Its approximately
9.6 kb genome contains an open reading frame (ORF) that codes
for a 3000 amino acid residue polyprotein precursor [17] that is
cleaved by cellular and viral proteases into three structural pro-
teins (core, E1, E2) and seven nonstructural proteins (p7, NS2,
NS3, NS4a, NS4B, NS5A, and NS5B) [138].
In the vast majority of infected individuals, HCVestablishes a
persistent and life-long infection via highly effective viral im-
mune evasion strategies [139–143]. The formation of double-
stranded RNA (dsRNA) intermediates during HCV genome
replication induces cellular dsRNA-sensingmachinery, which in
turn leads to the activation of proteins involved in antiviral
response, including interferons (IFNs), interferon regulatory
factors (IRFs), signal transducers and activators of transcription
(STATs), interferon stimulated genes (ISGs) and NF-κB [144].
The HCV core, E2, NS3, and NS5A proteins counteract this
cellular response through a variety of mechanisms, including
NS5A and E2 mediated suppression of dsRNA-activated kinase
PKR [139,142]. HCV is also very effective in subverting T-cell
mediated adaptive immunity [140,141]. Although the under-
lying mechanisms are still unclear, it is believed that the persis-
tence of HCV infection is due in part to the selection of
quasispecies that have escaped the host immune response [139].
Infection with HCV causes active inflammation and fibrosis,
which can progress to cirrhosis and ultimately lead to tumor
development. Numerous co-factors for the development of HCV-
associated HCC exist, including co-infection with HBV and
excessive alcohol consumption [145]. While it is currently
thought that chronic inflammation and cirrhosis play key roles
in HCV-induced carcinogenesis, the exact underlying mechan-
isms are not fully understood [146]. Moreover, the multiple
functions of HCV proteins and their impact on cell signaling
have led to the idea that both viral and host factors also play a role
in HCC. Core, NS3, NS4B, and NS5A have each been shown to
be transforming in murine fibroblasts [147] and transgenic mice
expressing HCV core protein develop HCC [148,149]. In ad-
dition, HCV proteins have also been reported to activate cellular
oncoproteins and inactivate tumor suppressors, such as p53
[150], CREB2/LZIP [151], and the retinoblastoma protein (pRB)
[152]. Finally, HCV causes genome instability, suggesting that
certain HCV proteins may have a mutator function [153]. A
Fig. 2. Schematic depiction of the major biological activities that contribute to
the transforming activities of HCV. See text for details.
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is depicted on Fig. 2.
5.2. DNA tumor viruses
The human DNA tumor viruses are a diverse group with
varied structures, genome organizations, and replication strate-
gies. Certain DNA tumor viruses, such as HPV, EBV, HBV, and
KSHV, cause malignancies in their natural hosts, whereas other
DNA tumor viruses, such as human adenoviruses, can transform
cultured cells and only cause tumors in heterologous animal
models. Unlike oncogenes encoded by animal retroviruses,
DNA tumor virus oncogenes are of viral, not cellular, origin and
are necessary for replication of the virus (reviewed in [154]). In
addition to elucidating the etiology of several human diseases,
analysis of the DNA tumor virus oncoproteins has revealed
mechanisms controlling mammalian cell growth, ultimately
leading to the discovery of cellular tumor suppressor genes.
Studies on the small DNA tumor viruses, which include the
adenoviruses, polyomaviruses, and papillomaviruses, have been
instrumental in elucidating the underlyingmolecular mechanisms
of virus-induced cell transformation. Although these viruses are
evolutionarily distinct, the striking similarities in their transform-
ing functions emphasize themutual need of these viruses to utilize
the host cell's replication machinery for efficient viral replication.
Much of the understanding of the actions of the small DNA tumor
virus oncoproteins has been derived from the study of the physical
associations of the viral oncoproteins with a variety of cellular
tumor suppressors, most notably the associations of adenovirus
E1A (Ad E1A), SV40 large Tantigen (TAg) andHPVE7with the
pRB family and adenovirus E1B (Ad E1B), SV40 TAg, and HPV
E6 with p53 (reviewed in [27,155,156]).
The first major cellular tumor suppressor that was found to
be targeted by small DNA tumor virus oncoproteins is pRB,
which was identified as the 105 kDa protein associated with Ad
E1A in adenovirus-transformed cells [157,158], and has sub-sequently been identified as a cellular target for SV40 Tag [159]
and HPV16 E7 [160]. The binding of Ad E1A, SV40 TAg, or
HPV E7 to pRB results in the disruption or alteration of cellular
complexes that normally contain pRB, resulting in inactivation
of growth regulatory functions [161–164]. Cells expressing
E1A, SV40 TAg, or HPV E7 display increased levels of free
E2F with associated loss of cell cycle dependent regulation of
E2F responsive genes [165,166]. E2F responsive genes play
key roles in cell cycle progression, and thus the association of
small DNA tumor virus oncoproteins with pRB ultimately
results in S-phase induction, an essential aspect of these viruses'
life cycles. Despite the fact that the core pRB binding sites of
SV40 TAg, HPV E7, and Ad E1A are similar, the functional
consequences of viral oncoprotein association are different.
Whereas Ad E1A inactivates pRB by binding both hypo- and
hyper-phosphorylated forms [163], SV40 TAg specifically
interacts with G1-specific, growth suppressive hypophosphory-
lated form [167] and HPV16 E7 preferentially binds hypopho-
sphorylated pRB [168,169] and targets pRB for proteasome
mediated degradation [170–172]. The second major cellular
tumor suppressor that is targeted by small DNA tumor virus
oncoproteins is p53, which was originally detected as a cellular
protein complexed with SV40 TAg in SV40-transformed cells
[173,174], and has since been shown to also complex with high-
risk HPV E6 and Ad E1B [175,176]. The p53 protein was
initially classified as an oncogene because it was cloned from a
cancer cell line and contained a point mutation, and it was only
later discovered that the wild type form has tumor suppressor
activity [177,178].
The interaction between SV40 TAg, HPV E6, and Ad E1B
with p53 results in the inhibition of p53′s tumor suppressor
activities [179–181]. p53 is a sequence specific, DNA binding
transcriptional activator [182,183]. It is not required for normal
cellular proliferation, but rather integrates signal transduction
pathways that sense cellular stress, and thus has been referred to
as a “guardian of the genome” [184]. Unlike the case with SV40
TAg, HPV E7, and Ad E1A, there is no structural similarity
between SV40 TAg, HPV E6, and Ad E1B; this lack of struc-
tural similarity is reflected in the differences between their
interactions with p53. The metabolic half-life of p53 is extended
in cells that express SV40 TAg or Ad E1B; consequently p53
levels are higher in these cells than in normal cells [185,186].
On the other hand, p53 levels in high-risk HPV E6 expressing
cells are lower than in their normal counterparts [187,188], due
to induction of p53 degradation through ubiquitin-mediated
proteolysis [189].
5.2.1. Human papillomavirus (HPV)
Papillomaviruses (PVs) are a group of small, non-enveloped,
double-stranded DNA viruses that constitute the Papillomavir-
idae family. These viruses infect squamous epithelia of a variety
of species [190]; to date, approximately 200 human papilloma-
virus (HPV) types have been described [191]. HPVs cause a
range of epithelial hyperplastic lesions and can be classified into
two groups: mucosal and cutaneous. These groups can be further
divided into low- and high-risk, depending on the associated
lesion's propensity for malignant progression.
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they are associated with a rare, genetically determined skin
disease, epidermodysplasia verruciformis (EV). These lesions
can progress to skin cancers particularly in sun-exposed areas of
the body. Skin cancer in EV patients was the first HPV cancer
type that was associated with HPV infections [192–196]; more
recent studies have revealed that HPV5 and 8 as well as related
cutaneous HPVs may contribute to the development of non-
melanoma skin cancers (NMSC), particularly in immunecom-
promised patients [197,198]. Infections with cutaneous HPVs
appear extremely frequently in the general population and some
of these viruses, even the presumed high-risk HPV5, may be part
of the normal “flora” of the skin as they can be detected in
follicles of plucked hair [199,200]. The mechanistic contribu-
tions of cutaneous HPVs and their interplay with other co-factors
that may result in NMSC development remains the subject of
intense study (reviewed in [201]). It has been shown that E6
proteins of cutaneous HPVs can target the proapoptotic Bcl-2
family member, Bak, for degradation. Bak plays an important
role in signaling apoptosis in response the UV irradiation and
hence it has been postulated that cutaneous HPVexpressing cells
may be less prone to undergo apoptosis after UV induced DNA
damage [202]. This may lead to survival and expansion of HPV
containing cells with extensive genomic aberrations, which may
contribute to transformation. Some cutaneous HPVs exhibit
bona fide transforming activities in cultured cells [203–206].
Moreover, skin hyperplasia and skin tumors develop in trans-
genic mice that express early region genes of cutaneous HPVs
[207,208]. HPV genomes are often found in only a subset of the
cancer cells suggesting that either cutaneous HPVs may con-
tribute to initiation of carcinogenesis but are not be required for
maintenance of the transformed phenotype, or that they con-
tribute to transformation through non cell autonomous mechan-
isms (reviewed in [201]).
The concept of low-risk and high-risk HPVs has been most
clearly established with the mucosal HPVs. The low-risk muco-
sal HPVs, such as HPV6 and 11, cause genital warts, whereas the
high-risk mucosal HPVs, such as HPV16 and 18, cause
squamous intraepithelial lesions that can progress to invasive
squamous cell carcinoma. HPV is also associated with oral and
other anogenital malignancies, however, it is most commonly
associated with cervical cancer; in fact, over 99% of all cervical
cancers are associated with high-risk HPV infections. Both
epidemiological and molecular evidence strongly supports the
link between infection with high-risk HPVs and the develop-
ment of cervical cancer. Nonetheless, the incidence of malignant
progression of high-risk HPV associated lesions is relatively
low; malignant progression usually occurs with other risk
factors, such as decreased immune function, and/or after a long
latency period after other genomic alterations in the host cell
DNA have occurred. Smoking and prolonged use of birth control
pills have also been implicated as risk factors for progression
(reviewed in [209]). Maybe most intriguing, Fanconi anemia
(FA) patients often develop squamous cell carcinomas at ana-
tomical sites that are susceptible to HPV infections. It has been
reported that oral carcinomas in FA patients are more frequently
HPV positive than in the general population [210]. Hence,certain aberrations in the FA pathway may predispose to malig-
nant progression of HPV associated lesions. Interestingly, the
ability of HPV E7 to induce genomic instability is increased in
FA derived cells, thus providing a potential mechanistic rational-
ization for these findings [211]. The molecular mechanisms by
which high-risk HPV causes cervical cancer have been studied
extensively, and numerous viral and host interactions that may
contribute to transformation and malignancy have been de-
scribed (reviewed in [27]).
During carcinogenic progression the HPV genome frequently
integrates into a host cell chromosome and, as a result, the viral
oncoproteins, E6 and E7, are the only viral proteins that are
consistently expressed inHPV positive cervical carcinomas. Viral
genome integration is a terminal event for the viral life cycle and
often results in deletion and/ormutation of other viral genes.Most
significantly, expression of the transcriptional repressor E2 is
often lost during integration. Moreover, the viral E6/E7 genes are
expressed from spliced mRNAs that contain cellular sequences
which results in increased mRNA stability. Hence, HPV genome
integration is often associated with higher, dysregulated E6/E7
expression [212]. Persistent expression of E6 and E7 is necessary
for maintenance of the transformed phenotype of cervical
carcinoma cells [213,214]. The expression of high-risk HPV E6
and E7 immortalizes primary human keratinocytes [215,216], and
when grown as organotypic “raft” cultures these cells display
histopathological hallmarks of high-grade premalignant lesions
[217]. However, these cells remain non-tumorigenic at low
passages after immortalization; tumorigenic progression is not
observed until long-term passaging in vitro or after the
transduction of an additional oncogene [218–220]. Moreover,
transgenic mice with expression of HPV E6 and E7 require low-
dose estrogen for the development of cervical cancer [221]. This
situation mimics the progression of high-risk HPV positive
cervical lesions, a process that occurs with a low frequency and
requires the acquisition of additional host cellular mutations
(reviewed in [222]).
HPVs have transforming properties in a number of rodent
cell lines, and the transforming potential correlates with their
clinical classification as high-risk and low-risk. Mutational
analyses have revealed that E7 encodes the major transforming
function [223–226], while E6 does not score as a major trans-
forming activity in most assays. High-risk HPV E7 also scores
in the classical oncogene cooperation assay in baby rat kidney
cells [223,227], whereas E6 can cooperate with ras in baby
mouse kidney cells [228]. High-risk HPVs can extend the life
span of primary human genital epithelial cells, and E6 and E7
are necessary and sufficient for this activity [226,229–233].
As mentioned previously, the transforming activities of the
high-risk E6 and E7 oncoproteins is related to their ability to
associate with and dysregulate cellular regulatory protein com-
plexes, most notably p53 and pRB (reviewed in [155]). As p53
and pRB normally control cellular proliferation, differentiation,
and apoptosis, the abrogation of their normal biological acti-
vities places such a cell at a risk of malignant progression.
In addition, high-risk HPV E6 and E7 expressing cells have a
decreased ability to maintain genomic integrity [234]. The high-
risk HPV E7 oncoprotein acts as a mitotic mutator and induces
Fig. 3. Schematic depiction of the major biological activities that contribute to
the transforming activities of high-risk mucosal HPVs. See text for details.
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bridges, unaligned or lagging chromosomes, and most notably
multipolar mitoses [235]. Multipolar mitoses are histopathologi-
cal hallmarks of high-risk HPV associated cervical lesions and
cancer [236] and are caused by the ability of high-risk HPV to
uncouple centrosome duplication from the cell division cycle
[237,238]. Hence, HPV E6/E7 oncoproteins mechanistically
contribute to initiation and progression of cervical cancer (Fig. 3).
5.2.2. Hepatitis B virus (HBV)
It is estimated that over 400 million people worldwide are
chronic carriers of HBV [239]. The vast majority of infections
are asymptomatic, and the non-cytopathic HBV [240] does not
cause a significant immune response after the initial infection,
presumably at least in part because HBVentry and expansion do
not induce the expression of any cellular genes [142,241].
Nonetheless, HBV is a major etiological factor in the develop-
ment of HCC, as 15–40% of infected individuals will develop
chronic active hepatitis (CAH) which can in turn lead to
cirrhosis, liver failure, or HCC [242,243]. This development is
accelerated by the exposure to environmental carcinogens in-
cluding aflatoxin B, cigarette smoke, and alcohol [146]. CAH is
characterized by liver cell necrosis, inflammation, and fibrosis,
and it is believed that the resulting cirrhosis may eventually lead
to HCC due to the fact that the rapid regeneration of hepatocytes
following constant necrosis may lead to the accumulation of
mutations and the subsequent selection of cells with a carcino-
genic phenotype [244]. Indeed, patients with cirrhosis are more
likely to develop HCC than patients without cirrhosis [245,246].
While it appears that both CAH and cirrhosis contribute to the
development of liver carcinogenesis, there is also evidence, such
as the correlation between serum HBV DNA level and risk of
HCC [247], suggesting a direct oncogenic contribution of HBV
to the carcinogenic process. Therefore, it appears that the cause
of HBV-associated HCC is a combination of HBV encoded
oncogenic activities along with the synergistic effects of chronic
inflammation.HBV has a circular, partially double-stranded, DNA genome
with four overlapping open reading frames (ORFs) that encode
for the envelope (preS/S), core (preC/C), polymerase, and X
proteins [248]. Like retroviruses, the replication of HBV is
dependent on reverse transcription; unlike retroviruses, integra-
tion of the viral genome into the host chromosome is not
necessary for viral replication but does allow for persistence of
the viral genome (reviewed in [249]). The integration event
precedes tumor development, as the HBV genome is often found
integrated in the host chromosome of patients with both CAH
and HCC [250,251]. HBV integration is a dynamic process, as
chronic inflammation together with increased proliferation of
hepatocytes may result in rearrangements of integrated viral and
adjacent cellular sequences [245]. Moreover, the integration
event can result in chromosomal deletions and transpositions of
viral sequences from one chromosome to another [252,253];
consequently, HBV integration may result in genomic instability
[254,255] as well as activation of proto-oncogenes [256–260].
However, integration of the HBV genome is not a necessary
prerequisite for malignant progression as approximately 20% of
patients with HBV-associated HCC do not display evidence of
integration [250].
Examination of viral DNA sequences present in HCC has
provided insight into additional oncogenic mechanisms of HBV.
Sequences encoding the HBV X protein (HBx) and/or truncated
envelope PreS2/S viral proteins are expressed in the majority of
HCC tumor cells. Additionally, a novel viral hepatitis B spliced
protein (HBSP) has been identified in HBV-infected patients
[261]. However, the mere expression of such proteins does
not confirm their role in HCC development and further studies
are necessary to determine their potential contributions to HCC
development.
HBx is a 154 amino acid multifunctional regulatory protein
that is highly conserved among all of the mammalian hepadna-
viruses [262], indicating that it likely plays an important role in
the viral life cycle. The expression of HBx is maintained
throughout all stages of carcinogenesis, including in cells with
integrated HBV genomes [263–268]. Studies of HBx in cultured
cells and transgenic animals support a role for HBx in
transformation and have demonstrated that HBx functions as a
regulatory protein for viral replication and, in the case of wood-
chuck hepatitis virus (WHV), is required for efficient infectivity
[269–272]. In addition, in vitro and in vivo studies indicate that
HBx plays an important role in the control of cell proliferation
and viability [273–275]. The findings from studies of the bio-
logical functions of HBX can be summarized as follows: 1) The
HBx protein acts on cellular promoters via protein–protein
interactions and exhibits pleiotropic effects that modulate
various cell responses to genotoxic stress, protein degradation,
and signaling pathways (reviewed in [276]), ultimately affecting
cell proliferation and viability [277,278]. Specifically, HBx
stimulates signal transduction pathways such as MAPK/ERK
and can also upregulate the expression of genes such as c-Myc,
c-Jun, NF-κB, AP-1, Ap-2, RPB5 subunit of RNA polymerase
II, TATA binding protein, and CREB [279]. 2) HBx regulates
proteasomal function [280–282]. 3) HBx affects mitochondrial
function [283,284]. 4) HBx protein modulates calcium
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instability [287].
In addition to HBx, the HBV genome encodes a second
group of regulatory proteins: the PreS2 activators [large surface
proteins (LHBs) and truncated middle surface proteins
(MHBst)] [288–291]. More than one-third of HBV-integrates
in HBV related HCC encode functional MHBst transactivators
[292,293], supporting the biological significance of PreS2 acti-
vators. The PreS2 activators are derived from the HBV sur-
face gene ORF, which consists of a single open reading frame
divided into three coding regions, preS1, preS2, and S. Large
(LHBs; preS1+preS2+S), middle (MHBs; preS2+S), and
small (SHBs; S) envelope glycoproteins can be synthesized
through alternate translational initiation [288,290,291]. The
LHBs and MHBst display transactivation activities; their tran-
scriptional activator function is based on the cytoplasmic orien-
tation of the PreS2 domain. PreS2 activators upregulate COX-2
and cyclin A and induce cell cycle progression [294]. Con-
sistent with this notion, transgenic mice expressing MHBst in
the liver displayed increased hepatocyte proliferation rate and
an increased occurrence of liver tumors [295].
In addition to sequences encoding for HBx and truncated
envelope PreS2/S viral proteins, a novel viral hepatitis B spliced
protein (HBSP) has been identified in HBV-infected patients
[261]. The spliced HBV RNA encoding for HBSP can be
reverse-transcribed and encapsidated in defective HBV particles
or expressed as HBSP [261]. HBSP induces apoptosis without
cell cycle block in an in vitro tissue culture model, and HBSP
antibodies are present in the serum of 45% of chronic hepatitis
patients [296]. Moreover, there seems to be a correlation be-
tween the presence of HBSP antibodies, viral replication and
liver fibrosis [296].
HBV-associated liver carcinogenesis is viewed a multi-
factorial process (Fig. 4). The integration of the HBV genome
into the host chromosome at early stages of clonal tumor ex-
pansion has been demonstrated to both affect a variety of cellular
genes as well as exert insertional mutagenesis, while chronicFig. 4. Schematic depiction of the major biological activities that contribute to
the transforming activities of HBV. See text for details.liver inflammation confers the accumulation of mutations in the
host genome. Additionally, HBV encoded HBx, PreS2 activa-
tors, and HBSP may exert oncogenic functions. However,
exactly how these viral factors contribute to higher risks of HCC
development remains unclear. Further studies are necessary to
reveal the molecular mechanisms underlying HBV-associated
HCC development. Moreover, since host genomic background
plays a role in the final disease outcome, an evaluation of the
genetic factors in both the host and viral genome that cause a
predisposition to hepatocarcinogenesis will help elucidate the
carcinogenic mechanisms involved in HCC development.
5.2.3. Epstein–Barr virus (EBV)
EBV is a ubiquitous double-stranded DNA virus of the γ
herpesviruses subfamily of the Lymphocryptovirus (LCV)
genus. Worldwide, more than 95% of the population is infected
with EBV [297,298]; the majority of EBV infections occurs
during childhood without causing overt symptoms. Post adoles-
cent infection with EBV frequently results in mononucleosis, a
self-limiting lymphoproliferative disease. EBV infects and
replicates in the oral epithelium, and resting B lymphocytes
trafficking through the oral pharynx become latently infected.
Infected B lymphocytes resemble antigen activated B cells, and
EBV gene expression in these cells is limited to a B cell growth
program, termed Latency III, that includes LMP1, LMP2a/b,
EBNAs -1, -2, -3a-3b, -3c, and -LP, miRNAs, BARTs, and
EBERs. These cells are eliminated by a robust immune response
to EBNA3 proteins, resulting in Latency I, a reservoir of latently
infected resting memory B cells expressing only EBNA1 and
LMP2. The differentiation of memory cells to plasma cells
results in reactivation of the replication phase of the viral life
cycle that includes expression of latency III gene products. In
addition, there is likely another amplification step by re-
infection of the epithelial cells followed by shedding virus in the
saliva to the next host.
All phases of the EBV life cycle are associated with human
disease. In immunecompromised individuals, infected cells in-
crease in number and eventually B cell growth control pathways
are activated, inducing transformation and leading to malig-
nancies such as NPC, BL, post-transplant lymphomas, and
gastric carcinomas [3]. EBV-associated malignancies follow
distinct geographical distributions and occur at particularly high
frequency in certain racial groups, indicating that host genetic
factors may influence disease risk [299,300]. EBV encodes
several viral proteins that have transforming potential, including
EBV latent membrane protein 1 and 2 (LMP1 and LMP2) and
EBV nuclear antigen 2 and 3 (EBNA2 and EBNA3). LMP1 can
transform a variety of cell types, including rodent fibroblasts
[301], and is essential for the ability of EBV to immortalize B
cells [302]. The multiple transmembrane-spanning domains and
the carboxyl terminus of LMP1 can interact with several tumor
necrosis factor receptor associated factors (TRAFs) [303,304];
this interaction results in high levels of activity of NF-κB, Jun,
and p38 in LMP1-expressing epithelial and B cells [305–307].
Through NF-κB, LMP1 provides survival signals by inducing
Bcl-2 family members, c-FLIP, c-IAPs, and adhesion molecules
[308]. LMP1 also upregulates the expression of numerous anti-
Fig. 5. Schematic depiction of the major biological activities that contribute to
the transforming activities of EBV. See text for details.
Fig. 6. Schematic depiction of the major biological activities that contribute to
the transforming activities of HHV-8/KSHV. See text for details.
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IRF-7 [309], matrix metalloproteinase-9 (MMP-9) and fibro-
blast growth factor-2 (FGF-2) [310]. A second viral membrane
protein, LMP2, is dispensable for transformation of naïve B
cells but is required for transformation of post-germinal center
B cells. LMP2 interacts with Lyn and Syk to mimic B cell-
receptor (BCR) signaling, including activation of the PI3K/
AKT survival pathway [311].
Other viral genes involved in transformation include EBNA2
and EBNA3. EBNA2, one of the first latent proteins to be de-
tected after EBV infection together with EBNA-LP, is a promis-
cuous transcriptional activator of both cellular and viral genes
[312,313] and is essential for B cell transformation [314].
EBNA3A, 3B, and 3C are hydrophilic nuclear transcriptional
regulators. EBNA3A and EBNA3C are essential for B cell trans-
formation in vitro, whereas EBNA3B is dispensable [315]. All
three EBNA3 proteins can suppress EBNA2-mediated transacti-
vation [316].
An excellent cell culture model system exists for the study of
EBV. In vitro infection of human peripheral blood B cells results
in the long-term growth of EBV transformed lymphoblastoid
cell lines (LCLs). These cell lines express Latency III gene
products which co-opt cellular pathways to effect cell growth.
LMP1 mimics CD40 to activate NF-κB, LMP2 mimics the B
cell antigen receptor, and EBNA-2, -LP, -3A, -3B, and -3C
mimic activated Notch. These pathways are constitutively active
and drive proliferation through a normal cell cycle cascade.
Moreover, there are no additional mutations to the RB or p53
pathways. Finally, if EBV signals are removed, the cells stop
proliferating; when LMP1 or EBNA2 expression is restored, the
cells begin to proliferate again. A summary of the role of EBV in
carcinogenesis is depicted on Fig. 5.
5.2.4. Kaposi's sarcoma-associated herpesvirus (KSHV)/
human herpes virus 8 (HHV8)
HHV8, also known as KSHV, is a recently discovered [18]
double-stranded human rhadinovirus of the γ-herpesvirus sub-family and, like other γ-herpesviruses, establishes life-long la-
tency inB cells. KSHVis associatedwith all forms ofKS, primary
effusion lymphomas (PELs), and multicentric Castleman's dis-
ease (MCD) [18,317–319]. The neoplastic potential of KSHV,
especially in immunecompromised individuals, is well-estab-
lished: epidemiological studies link KSHV to human malig-
nancies [3], KSHV transforms endothelial cells [320], and
KSHV-encoded transforming genes have been identified. The
current model of KSHV-induced malignancy involves a combi-
nation of proliferation, survival, and transformation mediated
by latently expressed viral proteins together with a paracrine
mechanism that is exerted directly or indirectly by the lytically
expressed v-cytokines and viral G-protein coupled receptor
(vGPCR) (Fig. 6). HIV-1 infected individuals are at the highest
risk for developing KS. Interestingly, KS lesions and tumors
appear to regress in patients who receive Highly Active Anti-
retroviral Therapy (HAART), suggesting that KSHV gene ex-
pression may be insufficient to initiate or maintain transformation
[321,322].
KS is an angioproliferative disease involving numerous an-
giogenic factors, endothelial cell (EC) growth factors, and pro-
inflammatory cytokines, including viral factors such as vIL-6,
vCCL-1, 2, and 3, and viral G-protein-coupled receptor (vGPCR).
VEGF is induced by vIL6 and subsequently promotes angiogen-
esis, and mouse cell lines that stably express vIL-6 and secrete
high levels of VEGF and are tumorigenic in nude mice [323]. A
notable property of the v-chemokines are their pro-angiogenic
activities [324,325]. Finally, vGPCR may contribute to KSHV-
associated neoplasia by inducing and sustaining cell proliferation
[326–330].
Latency expressed KSHV proteins that promote cell prolif-
eration and survival and thus may contribute to cellular transfor-
mation include the ORF73-71 locus-encoded latency associated
antigen (LANA, ORF73), viral cyclin (v-cyclin, ORF72), viral
FLICE inhibitory protein (vFLIP, ORF71), viral interferon regu-
latory factor 1 (vIRF-1), and the Kaposin/K12 gene. LANA sti-
mulates cellular proliferation and survival [331,332], v-cyclin
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pro-survival signaling [334,335], and kaposins induce cytokine
expression and cell growth [336].
In addition to the viral cytokines, vGPCR, and the five latency
genes mentioned, there are two KSHV-encoded constitutive
signaling membrane proteins, variable ITAM-containing protein
(VIP) and latency associated membrane protein (LAMP), that
play a role in KSHV-associated malignancies. VIP is encoded by
the K1 ORF and can transform rodent fibroblasts, which, when
injected into nudemice, induce multiple and disseminated tumors
[337]. VIP can also functionally substitute for the saimiri trans-
formation protein (STP) of herpesvirus saimiri (HVS) to induce
lymphomas in common marmoset monkeys and transgenic ani-
mals expressing VIP develop lymphomas and sarcomas [338]. In
addition to its direct transforming functions, VIP can induce
angiogenic factors and inflammatory cytokines [116]. LAMP,
which is encoded by the K15 ORF, exhibits potential mitogenic
and survival signaling via Src-family kinases and NF-κB acti-
vation and may promote cell survival via interaction with the Bcl-
2 related anti-apoptotic protein HAX-1 [339].
Finally, KSHV also contains several immune evasion genes,
including MIR1, MIR2, vIRFs, Orf45, and complement control
protein homolog (CCPH). The KSHVK3 and K5 proteins, MIR1
and MIR2, downregulate MHC I expression, thus inhibiting viral
antigen presentation. The KSHVvIRFs and Orf45 inhibit the host
interferon response, while CCPH inhibits complement-mediated
lysis of infected cells (reviewed in [327,340]). Together, these
immune evasion proteins ensure life-long viral persistence in
the host, and consequently contribute to KSHV-associated
pathogenesis.
6. Viruses implicated in human cancers
In addition to the above viruses and cancers, there also exist a
number of other cancers that may have an infectious etiology. A
causal role for these viruses in human malignancies remains to
be fully addressed; current knowledge regarding these viruses
and their potential role in human cancer will be summarized in
the following sections.
6.1. Polyomaviruses
The Polyomaviridae family is a group of non-enveloped,
small double-stranded DNA viruses that have been isolated
from humans, monkeys, rodents, and birds. The first poly-
omavirus to be discovered, mouse polyoma virus [9,341], is one
of the most aggressive carcinogenic viruses and causes tumors
in almost every tissue (polyoma) of susceptible mouse strains
[342,343]. Although it does not cause malignancies in humans,
mouse polyoma virus has been thoroughly studied and has been
instrumental in the establishment of systems for the study
of numerous eukaryotic cellular processes [344]. The second
polyomavirus discovered, SV40, was isolated as a contaminant
of early batches of the polio vaccine, which was produced in
African green monkey kidney cells [39]. SV40 naturally infects
the rhesus monkey where it establishes a low-level infection
and persists in the kidneys without any noticeable affects. SV40is closely related to two human polyomaviruses, BKVand JCV,
which were discovered in 1971 from the urine of a renal
transplant patient [40] and the brain of a patient with
progressive multifocal leukoencephalopathy [42], respectively.
Infection with BKV and JCV is widespread in humans and is
usually subclinical. However, in immunesuppressed patients,
BKV is associated with renal nephropathy [345,346] and JCV
can cause progressive multifocal leukoencephalopathy (PML)
[347,348]. More recently two additional novel putative human
polyomaviruses, termed KI and WU, have been isolated
[349,350].
SV40, BKV, and JCV can all transform cells in vitro and
induce tumors in rodents; additionally, the injection of poly-
omavirus transformed cells in animal models or the ectopic
expression of polyomavirus regulatory proteins in transgenic
animals also induces tumors (reviewed in [40,41,351]).
Together, these findings demonstrate the oncogenic potential
of the polyomaviruses. However, the association of these
polyomaviruses with human malignancy remains controversial.
A number of studies have implicated SV40 in a range of
human cancers, including mesothelioma, osteosarcoma, non-
Hodgkin lymphoma (NHL), and a variety of childhood brain
tumors. On the other hand, other studies have failed to demon-
strate an association of SV40 with human cancer, and the
question of whether the release of SV40 into the human
population through the polio vaccine contributed to the
development of human cancers remains a contentious issue.
Although in the 1950s approximately 100 million people were
exposed to SV40 through the polio vaccine in the US alone,
there is currently no evidence to suggest that SV40 infection is
widespread among the population or that there is an increase in
tumor burden among individuals who received the contami-
nated vaccine. Recently, studies have suggested that flawed
detection methods may account for many of the positive
correlations of SV40 with human tumors. In summary, the
studies performed to date have failed to provide conclusive
proof implicating SV40 as a human pathogen [352,353].
Like SV40, a role for BKV and JCV in human tumors has
been suggested, however, no conclusive proof exists that either
virus directly causes or acts as a cofactor in human cancer. The
search for a correlation between BKV and JCV and human
cancer is complicated due to the fact that both viruses are
ubiquitous in the population. With respect to JCV, there have
been reports of JCV variants in a variety of human brain tumors;
these studies have not, though, demonstrated any causal effects
(reviewed in [354]). There is also correlative data regarding the
potential role of BKV in human cancer. BKV persistently
infects epithelial cells in the urinary tract, and some studies have
linked BK virus infections to prostate cancer [355].
6.2. Adenoviruses
Members of the Adenoviridae family cause lytic and persis-
tent infection in a range of mammalian and avian hosts. In
humans, more than 50 different adenovirus serotypes have been
described. They can be divided into six species, designated A–F
[356]. Generally, clinically unapparent infection with these
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cytes or peripheral blood lymphocytes remain persistently in-
fected [357,358]. Although certain Ad serotypes are highly
transforming in cell culture and in animal models, early studies
indicated that these viruses may not associated with human
cancers [359–361]. This issue has been recently readdressed,
however, and one study reported detection of adenovirus DNA
in pediatric brain tumors [362]. However, a possible causal
relationship of Ad infection with the pathogenesis of malignant
brain tumors still remains unclear.
The transforming and oncogenic potential of adenoviruses
has been traditionally ascribed to the E1A and E1B oncopro-
teins, which are similar to SV40 TAg and high-risk HPV E7/E6
target pRb and p53, respectively. However, more recent studies
have suggested that, at least with some serotypes, E4 ORFs may
contribute to cellular transformation [363], potentially through a
“hit-and-run” mechanism [364]. Hence, the possible contribu-
tion of adenovirus infections to some aspects of human tumor
development may need to be carefully re-evaluated.
6.3. Human endogenous retroviruses (HERVs)
HERVs are sequences within the genome that resemble
infectious retroviruses (reviewed in [43,44,365]) that result from
ancestral exogenous retroviral infections that became incorpo-
rated into the germ line DNA. Today, HERVs constitute∼8% of
genome [366] and possess a similar genomic organization to
exogenous complex retroviruses such as human immunodefi-
ciency virus (HIV) and HTLV. Evolutionary pressure has
ensured the inactivation of HERVs, leading to the idea that
HERVs are merely “junk DNA”. However, recent evidence
suggests that some HERVs may have both physiological and
pathological roles, including roles in human malignancy.
While the exact role(s) of HERVs has yet to be fully
elucidated, some studies have suggested that HERVs might play
a role in carcinogenesis. Specifically, some HERVs have been
implicated in human malignancy, due mainly to the increased
expression of the HERV mRNA [367], functional protein [368],
and retrovirus-like particles [369] in certain cancers. HERVs
may also be linked to the generation of new promoters [370] or
the activation of proto-oncogenes [371].
Current studies focus on the association of HERV-K with a
number of cancers, including germ cell tumors, in particular
seminomas [368,372], breast cancer, myeloproliferative disease,
ovarian cancer [373], melanoma [374,375], and prostate cancer
[376]. Some seminomas have been reported to express HERV-K
proteins and sometimes release defective viral particles [369].
HERV-K proteins Rec and Np9 can bind the promyelocytic
leukemia zinc finger (PLZF) protein [377], and hence it has been
suggested that HERV-encoded proteins may contribute to the
carcinogenic process.
None of these studies, however, provides compelling evi-
dence that HERV-K expression contributes to tumorigenesis
and it is equally possible that HERV gene expression may
merely represent a corollary of cell transformation.
Recently, it has been discovered that recurrent chromoso-
mal translocations importantly contribute to the development ofhuman solid tumors. Interestingly, some of these translocations
result in HERV-K regulatory sequences being placed upstream of
the coding sequences of ETS transcription factor familymembers.
Since HERV-K regulatory sequences are androgen responsive,
such translocations cause aberrant, androgen-induced expression
of these ETS transcription factors [376]. This is an exciting
finding as the result of such translocations is conceptually si-
milar to insertional mutagenesis, where retroviruses contribute to
carcinogenesis by integrating in the vicinity of cellular proto-
oncogenes, thereby causing their aberrant expression.
6.4. Human mammary tumor virus (HMTV)/Pogo virus
The idea of the existence of a human breast cancer virus
followed Bittner's demonstration that a virus, MMTV, can
cause breast cancer in mice [378]. While studies in the last 7
decades have failed to provide compelling evidence proving this
model, a possible viral etiology for some breast cancers remains
an active and controversial area of research. A number of
reports have suggested that an MMTV-related virus, human
mammary tumor virus (HMTV), sometimes also referred to as
the Pogo virus, may be associated with human breast cancers
(reviewed in [45]).
A 660-bp sequence similar to the MMTV env gene was
reportedly detected in 38% of American women's breast cancers
[379]; subsequent polymerase chain reaction (PCR) amplifica-
tions detected other gene segments homologous toMMTV [380].
Moreover, env and LTR HMTV genes have been found inserted
into several chromosomes [381], reminiscent of MMTV, which
induces oncogenesis via insertional mutagenesis. The entire
HMTV genome, which contains hormone response elements, has
also been detected in fresh breast cancers [381]; additionally,
primary breast cancer cells produce HMTV particles in vitro
[382]; additionally, HMTV particles with morphogenic and
molecular characteristics similar to MMTV were reported in
primary breast cancer cells [382]. However, other groups have
been unable to detect such sequences in breast cancers [383].
Since many HERVs are similar to MMTV, it is not clear
whether HMTVrepresents an infectious entity, and/or if it can be
acquired from infected mice as has been suggested by an
epidemiological study, which reported that regions where Mus
domesticus infestations are prevalent have the highest incidence
of human breast cancer [384]. In possible support of an infec-
tious etiology, human MMTV receptor-related proteins have
been cloned [385]. Moreover, it has recently been reported that
MMTV replicates rapidly and successfully in human breast
cancer cells [386].
Even if HMTV-like sequences are indeed expressed in some
human breast cancers, there is presently no compelling evidence
that unambiguously supports a mechanistic contribution of such
viruses to breast cancer development.
6.5. Xenotropic murine leukemia virus-related virus (XMRV)
The finding that the familial prostate cancer susceptibility
locus Hpc1 is linked to mutations in the structural gene for
RNase L [387], an effector in the interferon induced innate viral
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RNase L might allow for infection with an oncogenic virus, thus
leading to the development of PC. Xenotropic murine leukemia
virus-related virus (XMRV) is a recently described gamma
retrovirus that was discovered using PCR cloned codas from
tumors from PC patients with a mutation in RNase L [389].
XMRV protein was detected in the stoma and hematopoetic cells
of the prostate tumors, but was not detected in the actual cancer
cells [389]. Therefore, it is unclear whether XMRV may be
causally associated with prostate cancer. However, it is possible
that XMRVmay contribute to tumorigenesis through an indirect
mechanism.
6.6. Torque teno virus (TTV)
Torque teno virus (TTV) is a single-stranded circular DNA
virus of the Circoviridae family and was first found in a
patient with non-A–E-hepatitis [46]. Since its initial discovery,
a large number of TTV types and subtypes that display
substantial genomic variation have been described [390–395].
TTV is acquired in early childhood [396,397] and remains
prevalent in adults [391,398,399]. Numerous attempts to link
TT viruses to pathogenicity, particularly liver diseases, have
thus far been unsuccessful [400–402]. However, one study did
suggest that a high TTV load may have prognostic significance
in HCV-associated liver disease, but the issue of whether high
TTV load mediates HCV-associated disease progression
remains to be addressed. Another study demonstrated a
relatively high prevalence of TTV-related DNA sequences in
human cancers, specifically gastrointestinal cancer, lung
cancer, breast cancer, and myeloma [403]. No causal relation-
ship between TTV infection and carcinogenesis can be drawn
from this study, as normal control tissues were not included.
7. Concluding remarks/perspectives
The study of virus-associated cancers has provided many
critical insights into key mechanisms of carcinogenesis. The
initial work that showed that some animal cancers were caused
by retroviruses firmly established the concept that cancers can
be caused by infectious agents. Analyses of retroviral integra-
tion sites and retrovirally transmitted transforming genes
yielded a treasure trove of information on oncogenes and
tumor suppressors that were later found to be similarly mutated
in human malignancies. While there is no firm evidence that
human tumors are caused by retroviral transmission of activated
oncogenes, these studies, nevertheless, provided much of the
foundation of modern oncology.
The main difference between these early studies with trans-
forming animal retroviruses and human tumor viruses is that
oncogenes of human tumor viruses are viral genes, rather than
mutated versions of cellular genes that were accidentally assim-
ilated during the viral replication cycle. These human tumor-
virus oncogenes play central roles in viral life cycles and their
oncogenic potential is a manifestation of these activities.
Some viruses, most notably the high-risk HPVs, play
essential roles in the initiation as well as progression of cancersand continued expression of their viral transforming activities is
necessary for the maintenance of the transformed phenotype.
This concept is supported by studies that showed that the major
targets of the HPV E6 and E7 oncoproteins, the p53 and pRB
tumor suppressors, are retained in a dormant, yet functional
state, in HPV positive cervical cancer cell lines, whereas the pRB
and p53 tumor suppressor sustained mutations in HPV negative
cervical carcinoma lines [188]. Hence, these proteins are pre-
dicted to be excellent targets for therapy. This concept is im-
pressively supported by numerous studies that showed that
cervical cancer cell lines that are manipulated to lose E6/E7
oncogene expression promptly undergo growth arrest, senes-
cence, and/or apoptosis and that this is related to reactivation of
the p53 and pRB tumor suppressor pathways [213].
Since HPV E6 and E7 lack intrinsic enzymatic activities, the
development of E6/E7 specific antivirals is difficult. HPV E6 and
E7, like many viral oncoproteins, function by associating with
host cellular proteins, including enzymes such as ubiquitin ligases
and histone modifying enzymes. It will be important to determine
whether targeting such enzymes will have a specific therapeutic
benefit [404]. Last, but not least, viral proteins that are consis-
tently expressed in virus-associated tumors are attractive targets
for development of therapeutic vaccination strategies.
It will also be interesting to explore whether the alterations in
cell signaling networks due to viral oncogene expression renders
infected cells uniquely dependent on (“addicted to”) specific
cellular signal transduction pathways. The concept of synthetic
lethality in yeast predicts that such pathways may be excellent
candidates for therapeutic intervention [405]. The availability of
genome wide RNAi and cDNA libraries should make such
approaches feasible. Given that the pathways targeted by viral
oncoproteins are often mutated in non-virus-associated cancers,
one might predict that such studies may reveal viable therapeutic
targets for numerous malignancies.
In some cases, however, the virus may only contribute to one
specific step in the carcinogenic process and its continued
expression may thus not be necessary for the maintenance of the
transformed state. This is sometimes referred to as “hit-and-run”
carcinogenesis. In these cases, it is very difficult to conclusively
demonstrate that the virus indeed did contribute to the develop-
ment of a given tumor. The relatively recent realization that some
viruses encode proteins that subvert genomic stability lends
some mechanistic credence to this model (reviewed in [27]).
Accordingly, a virus-infected cell would be significantly more
promiscuous for accumulation of genetic aberrations that even-
tually may lead to tumor formation. One might also imagine that
viral proteins that alter the histone code may permanently
modify the epigenetic imprint of a host cell and the resulting
alterations in gene expression may contribute to cellular
transformation.
Another possibility is that viral gene expression is only
maintained in some tumor cells. This has been observed with
some HPV containing non-melanoma skin cancers [201]. While
this is consistent with a “hit-and-run” mechanism, it may also
indicate that viral oncogene expression might provide a growth
promoting activity indirectly through secreted factors that are
necessary for optimal tumor growth.
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cancer type does not necessarily imply that the virus mech-
anistically contributes to the genesis of the tumor. It may simply
represent the fact that tumor cells represent a particularly fertile
ground for viral replication. Tumors often contain a larger
population of proliferative cells than the surrounding normal
tissue and hence might be particularly permissive for viral
replication. In addition, they often are subject to decreased
surveillance by the immune system. Given the availability of
new tools to discover virus sequences in tumors, this issue will
represent a major challenge for the future.
Host defense mechanisms play a significant role in modu-
lating viral carcinogenesis. Their protective role is most clearly
illustrated by the fact that Epstein–Barr virus in most cases
establishes life-long asymptomatic latency and tumors arise
when immunesurveillance of the host organism is weakened or
fails. Similarly, non-melanoma skin cancers associated with
cutaneous HPV infections are a frequent complication in organ
transplant patients.
However, in other cases the host response to viral infection
and/or their cellular consequences significantly contributes to
the carcinogenic process. While infection of liver cells with
hepatitis viruses does not appear to cause a major immune
response to the initial infection it causes extensive inflamma-
tion. This causes cell damage and production of genotoxic
reactive oxygen species, which in concert with rapid prolifera-
tion due to regenerative processes and potentially genomic
destabilization due to viral gene expression, may lead to
accumulation of mutations that eventually lead to carcinogenic
progression.
The infectious etiology of certain cancers affords the unique
possibility for prophylactic vaccination. Since vaccination with a
weakened live virus is not an option for oncogene carrying vi-
ruses, it is necessary to develop “subunit vaccines” consisting of
immunogenic recombinant viral proteins. Such a vaccine has
been developed for HBVand has proven highly efficacious. HBV
vaccines are relatively inexpensive; consequently, they are widely
used and have had a remarkable public health impact. Prophy-
lactic vaccines to prevent infections with the most abundant low-
risk and/or high-risk HPVs (HPV6, HPV11 and/or HPV16,
HPV18) are now commercially available. These vaccines consist
of recombinant L1 proteins that form virus-like particles (VLPs),
which induce a vigorous type-specific immune response and
show great promise (reviewed in [406]). Vaccination has to be
before the onset of sexual activity and it will be important to
determine how long the protection will last. However, since HPV-
induced cervical carcinogenesis is a slow process, it will be
several decades before there will be a noticeable decrease in cer-
vical cancer cases due to vaccination [407]. It will also be im-
portant to determine whether other high-risk HPVs that are not
targeted by the current vaccine preparations will fill the void and
become more abundant in the population. This would require
development and inclusion of VLPs corresponding to additional
HPV types to the vaccine preparations. Perhaps most significant,
these vaccines are extraordinarily expensive to produce. Since
most cervical cancer cases and deaths occur in medically
underserved patients, it is thus unlikely that the population thatwould profit the most from a prophylactic approach will gain
access to these vaccines in the near future.
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